Does OLMESARTAN MEDOXOMIL Cause Benign prostatic hyperplasia? 55 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 55 reports of Benign prostatic hyperplasia have been filed in association with OLMESARTAN MEDOXOMIL (OLMESARTAN MEDOXOMIL). This represents 0.5% of all adverse event reports for OLMESARTAN MEDOXOMIL.
55
Reports of Benign prostatic hyperplasia with OLMESARTAN MEDOXOMIL
0.5%
of all OLMESARTAN MEDOXOMIL reports
1
Deaths
51
Hospitalizations
How Dangerous Is Benign prostatic hyperplasia From OLMESARTAN MEDOXOMIL?
Of the 55 reports, 1 (1.8%) resulted in death, 51 (92.7%) required hospitalization, and 40 (72.7%) were considered life-threatening.
Is Benign prostatic hyperplasia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLMESARTAN MEDOXOMIL. However, 55 reports have been filed with the FAERS database.
What Other Side Effects Does OLMESARTAN MEDOXOMIL Cause?
Sprue-like enteropathy (3,482)
Gastrooesophageal reflux disease (1,819)
Acute kidney injury (1,587)
Weight decreased (1,569)
Haemorrhoids (1,316)
Diarrhoea (1,300)
Hiatus hernia (938)
Dizziness (885)
Large intestine polyp (839)
Constipation (796)
What Other Drugs Cause Benign prostatic hyperplasia?
TADALAFIL (596)
TAMSULOSIN (304)
FINASTERIDE (266)
PANTOPRAZOLE (261)
PREDNISONE (257)
ALBUTEROL (254)
ASPIRIN (243)
TIOTROPIUM (235)
RAMIPRIL (193)
AMLODIPINE (179)
Which OLMESARTAN MEDOXOMIL Alternatives Have Lower Benign prostatic hyperplasia Risk?
OLMESARTAN MEDOXOMIL vs OLMETEC
OLMESARTAN MEDOXOMIL vs OLODATEROL
OLMESARTAN MEDOXOMIL vs OLODATEROL\TIOTROPIUM
OLMESARTAN MEDOXOMIL vs OLOPATADINE
OLMESARTAN MEDOXOMIL vs OLUTASIDENIB